tci 2016 dutch clusters on stage
TRANSCRIPT
Titel presentatie[Naam, organisatienaam]
Working Day - Track: Modern cluster policyDutch clusters on stage
Ingrid Coninx, Hans Rijnten, Mirjam Mol & James Wilson
Dutch clusters on stage
Dutch Clusters on Stage
Ingrid Coninx, Wageningen Environmental ResearchHans Rijnten, Economic Board UtrechtMirjam Mol, Pivot ParkJames Wilson, Orkestra – Basque Institute of Competitiveness
Large variety
3
TCI GLOBAL CONFERENCE 2016Dutch clusters on the stage
Hans Rijnten, Economic Board Utrecht
November 10, 2016
Megatrend 1: Climate Change
Megatrend 2: Ageing population
Megatrend 3: Digitalisation
Economic Board UtrechtEconomic Research – our strenghts
Economic Board UtrechtTriple helix partners
• Societal challenge = economic opportunity
• Strategic agenda: o green economyo Life sciences & healtho Service innovation
• Private commitment (businesses)• Scalable• Reinforcement profile region
Economic Board UtrechtRegional agenda 2013-2020: Green, Healthy and Smart
EBU: Results 2015
Initiatief Bijdrage Vorm Omvang Spin off €
NOM; 033-Energy € 1,4 M Cofin. € 5 M € 90 M
Fiware € 0.94 M Cofin. € 2.64 M € 20 M
Dutch Game Garden € 0.750 M Cofin. € 2.25 M € 20 M
DGA - Control conference € 0.15 M Cofin. € 0.95 M € 2 M
‘Groen-gezond-slim’ fund € 1 M lening € 4 M PM.
NOMMIF € 0.55 M Cofin. € 0.675 M € 7,2 M
MIT-regelingen € 1 M Cofin. € 2 M € 6 MTotaal € 5,8 M variabel € 17,5 M € 145 M
www.pivotpark.com
Pivot ParkThe ecosystem
Mirjam Mol10 November 2016
● 13
Pivot Park is a unique park in the NetherlandsTHE place for innovative drug discovery research and development in the Netherlands: form target to market
Where chemistry and biology meet
Turn key facilities: state of the art laboratories, offices, completely furnished and equipped to start research or development activities
Unique core facilities: Modern equipment which is needed for biological, chemical and analytical lab research
two pilot plants
ultra high throughput screening facility with compound collection
R & D services (equipment / utilities / waste management) by a team of experts; customized solution for our customers
Cross-over Chemistry/Life Sciences
History
Analytics
HTSuHTSCompounds
Pilot Plants
Lab & Office facilities
• Fully equipped labs
• Open Access labs
• Flex labs
• Nuclear Magnetic Resonance
• Liquid Chromatography
• Mass Spectrometry
• Open Access HTS
• Flexible uHTS• Hit / Lead
optimization
• Up to 10 kg• GMP standard• Small
molecules• GMP/FDA
approved• Clinical trial
materials• Marketed
batches
Unieke faciliteiten, apparatuur, kennis en bedrijfsvoering
Growth of the Pivot Park Community
Pivot Park community (September 2016)
CROs
Product development
CMOs
Other services
Pivot Park community – R&D pathway (September 2016)
Acerta PharmaAPO-TAduro Biotech EuropeGlycostemInnatOssLead PharmaLitevaxModiquestNTRCOsteo-PharmaSynAffi x
3D-PharmXchangeAUTHOR!BioAxisBioXpertInProcess-LSPPivot Park Screening CentreSpinnovation AnalyticalQuality by DesignQuantitative SolutionsQuintilesZwiers Regulatory
AspenBioConnection ChemConnection
Arnold+Siedsma BAM Infra StruktonBogaerts en Groenen CVIS Thema groepDotcombusiness ESP Van Oss GroepFriday Life Sciences Hulshof Kroonen & GroenEkoy Investment Partners Rescop
RegistrationTarget discovery
Leaddiscovery
Leadoptimization
Pre-clinical development
Clinical phase I
Clinical phase II
Clinical phase III
Largescale manufacturing
Pivot Park CommunityBenefits of the ecosystem
• Inspiration by interaction• New opportunities for
collaboration• Diversity: from target to
market• Sharing high-end
facilities = cost reduction• Strong position in
regional, national and international knowledge infrastructure
Main trend in innovative entrepreneurship worldwide!
Facilitating open innovation
Closed innovatio
n
Open innovatio
n
From closed …
• Solo-creation• Transactions• IP legal drive• Academic research
funding by industry
• Large enterprises determine market access for innovation
… to open innovation:
• Co-creation• Networks/
Relationships• Entrepreneurial
drive• Commercial &
Academic research collaboration
• SMEs accelerate market access in innovation
Screening consortiaTKI Oncodrugs
TargetID HTS Hit
OptimisationLead Optimisation
DevelopmentCandidate
Clinical Development
Identification and development of compounds for different targets • NKI, NTRC, Covalution BioSciences and Lead Pharma targets• PPSC High Throughput Screening using their compound library• Leids Instituut voor Chemie (LIC) MedChem (in close collaboration with PPSC)• NKI testing • Lead Pharma, Covalution BioSciences and NTRC MedChem, H2L and LO
Objective: Find lead series/clinical candidates in the field of oncology and interest from big pharma
Covalution BioSciences